Zimmer Biomet Holdings, INC. Stock: price and directors' dealings · United States · SEC (Form 4)Follow the Zimmer Biomet Holdings, INC. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Zimmer Biomet Holdings, INC. has published 148 reports. Market capitalisation: €19.2bn. The latest transaction was reported on 9 September 2026 (Cession). Among the most active insiders: Winkler Lori. All data is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 10,403 of 29,063 companies
FCF yld 7.4%
Earn yld 3.7%
EV/EBITDA 12.1x
ROE 6.4%
Gross mgn 70%
Net mgn 8.6%
Debt/EBITDA 3.4x
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 September 2026
All Executives148 Thresholds0 Prospectus0 Other0
Declarations 148 total
▼ See remarks below. · Executives · 4 Sept 2026
3,000 shares @ US$98.35 Common Stock SEC:0001346672-26-000010:0
● Officer · Executives · 4 Sept 2026
3,000 shares @ US$98.3501 0.0015% mcap 3.8% of flow Common SEC144:0001959173-26-006759
◇ Grp Pres-Global Business · Executives · 1 Aug 2026
9,957 shares 0Common Stock SEC:0001783992-26-000004:0
● Grp Pres-Global Business · Executives · 1 Aug 2026
4,266 shares @ US$92.68 0.0022% mcap 100.0% of flow Common Stock SEC:0001783992-26-000004:1
● Former Officer · Executives · 16 Jul 2026
7,668 shares @ US$92.86 0.0041% mcap 63.2% of flow Common SEC144:0001959173-26-005253
● Former Officer · Executives · 24 Jun 2026
4,560 shares @ US$90.065 0.0023% mcap 100.0% of flow Common SEC144:0001959173-26-004849
◇ See remarks below. · Executives · 1 Apr 2026
6,626 shares 0Common Stock SEC:0002059755-26-000004:0
● See remarks below. · Executives · 1 Apr 2026
1,677 shares @ US$90.67 100.0% of flow Common Stock SEC:0002059755-26-000004:1
▼ SVP and CHRO · Executives · 12 Mar 2026
2,650 shares @ US$94.66 34.5% of flow Common Stock SEC:0001852191-26-000010:0
◇ Group Pres, EMEA · Executives · 6 Mar 2026
4,843 shares 0Common Stock SEC:0001864818-26-000008:0
◇ SVP and CHRO · Executives · 6 Mar 2026
3,935 shares 0Common Stock SEC:0001852191-26-000008:0
◇ Chairman, President and CEO · Executives · 6 Mar 2026
24,436 shares 0Common Stock SEC:0001757216-26-000008:0
◇ VP, Controller, CAO · Executives · 6 Mar 2026
1,363 shares 0Common Stock SEC:0001714585-26-000008:0
◇ Group President, Asia Pacific · Executives · 6 Mar 2026
7,050 shares 0Common Stock SEC:0001635943-26-000010:0
◇ Exec VP, CFO · Executives · 6 Mar 2026
10,217 shares 0Common Stock SEC:0001533149-26-000009:0
◇ See remarks below. · Executives · 6 Mar 2026
4,692 shares 0Common Stock SEC:0001346672-26-000008:0
◇ Group Pres, EMEA · Executives · 25 Feb 2026
3,182 shares 0Common Stock SEC:0001864818-26-000006:0
◇ SVP and CHRO · Executives · 25 Feb 2026
2,347 shares 0Common Stock SEC:0001852191-26-000006:0
◇ Chairman, President and CEO · Executives · 25 Feb 2026
19,090 shares 0Common Stock SEC:0001757216-26-000006:0
◇ VP, Controller, CAO · Executives · 25 Feb 2026
820 shares 0Common Stock SEC:0001714585-26-000006:0
◇ Group President, Asia Pacific · Executives · 25 Feb 2026
2,785 shares 0Common Stock SEC:0001635943-26-000008:0
◇ Exec VP, CFO · Executives · 25 Feb 2026
6,364 shares 0Common Stock SEC:0001533149-26-000007:0
◇ See remarks below. · Executives · 25 Feb 2026
2,626 shares 0Common Stock SEC:0001346672-26-000006:0
◇ Group Pres, EMEA · Executives · 20 Feb 2026
2,451 shares 0Common Stock SEC:0001864818-26-000004:0
◇ SVP and CHRO · Executives · 20 Feb 2026
1,845 shares 0Common Stock SEC:0001852191-26-000004:0
25 of 148 declarations
Load more (123 remaining) 关于 Zimmer Biomet Holdings, INC. Zimmer Biomet Holdings, Inc.(股票代码:ZBH)是一家全球医疗技术公司,专注于骨科和肌肉骨骼解决方案。该公司股票在美国纽约证券交易所上市,总部位于印第安纳州华沙。其历史可追溯至1927年,当时Zimmer Manufacturing Company在华沙成立。Zimmer Biomet于2001年成为一家独立的上市公司,随后在2015年通过收购Biomet进行了实质性扩张,从而形成了现在的公司名称。
该公司设计、制造和销售广泛的骨科植入物及相关设备组合,核心业务包括髋关节、膝关节和肩关节,以及用于四肢、创伤、颅颌面和胸腔应用的产品、骨水泥、手术产品以及集成数字和机器人技术。其产品包括机器人辅助手术平台、导航工具、软件驱动的工作流程和下一代植入物设计。对于投资者而言,Zimmer Biomet最好被视为一个广泛的骨科平台,而非单一产品公司:它服务于多个地区的骨科医生、医院、门诊手术中心、分销商和采购团体。
从竞争角度来看,该公司受益于悠久的运营历史、公认的品牌、庞大的现有客户群以及重要的全球制造和研发足迹。Zimmer Biomet在全球运营约300个设施,主要业务分布在美国、瑞士、爱尔兰和中国。其年度报告显示,美国约占其收入的58%,这使得美国市场对其商业表现和国内市场进入模式的持续转型都至关重要。
最近的发展具有战略重要性。Zimmer Biomet报告称,2025年净销售额为8.232 billion美元,这得益于市场增长、新产品推出以及对Paragon 28的收购。2025年,该公司还完成了对Monogram Technologies的收购,通过更自主的骨科技术路径扩展了其机器人和数字生态系统。2026年初,该公司强调了ROSA Knee with OptimiZe的推出和扩展,以及髋关节和膝关节植入物方面新的监管里程碑。总体而言,该投资案例结合了防御性择期手术特征、强大的创新强度以及旨在更快增长的骨科细分市场的有针对性的并购。